Vunakizumab Chemical Properties

form 

Liquid

color 

Colorless to light yellow

Vunakizumab Usage And Synthesis

Uses

Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a recombinant human IgGκ monoclonal antibody that targets IL-17A and inhibits its interaction with the IL-17 receptor. Vunakizumab can be used to study autoimmune diseases such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis and inflammatory arthritis[1].

References

[1] Chunlei Zhang, et al. A multicenter, randomized, double-blinded, placebo-controlled, dose-ranging study evaluating the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2022 Jul;87(1):95-102. DOI:10.1016/j.jaad.2022.01.005

Vunakizumab(1792181-33-9)Related Product Information

• Omalizumab
• Plozalizumab
• Naxitamab
• Necitumumab
• Bemarituzumab
• Narlumosbart
• Etokimab
• Atezolizumab
• Odronextamab
• Elezanumab